Journal of Clinical Oncology, Vol 25, No 16 (June 1), 2007: pp. 2171-2177
© 2007 American Society of Clinical Oncology.
DOI: 10.1200/JCO.2006.06.7447
Open-Label, Uncontrolled, Multicenter Phase II Study to Evaluate the Efficacy and Toxicity of Cetuximab As a Single Agent in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Who Failed to Respond to Platinum-Based Therapy
Jan B. Vermorken,
José Trigo,
Ricardo Hitt,
Piotr Koralewski,
Eduardo Diaz-Rubio,
Frédéric Rolland,
Rainald Knecht,
Nadia Amellal,
Armin Schueler,
José Baselga
From the Department of Medical Oncology, University Hospital Antwerp, Edegem, Belgium; Oncología Médica, Hospital la Vall d'Hebron, Barcelona; Servicio de Oncologia, Hospital Universitario 12 de Octubre; Servicio de Oncologia, Hospital Universitario, Clinico San Carlos, Madrid, Spain; Klinika Chemioterapii, Szpital im. L. Rydygiera, Krakow, Poland; Centre René Gauducheau, Nantes, France; Zentrum der Hals-, Nasen- und Ohrenheilkunde, Klinikum der Johann-Wolfgang-von-Goethe-Universität, Frankfurt; and Merck KGaA, Darmstadt, Germany
Address reprint requests to Jan B. Vermorken, MD, PhD, Department of Medical Oncology, University Hospital Antwerpen, Wilrijkstraat 10, B-2650 Edegem, Belgium; e-mail: Jan.B.Vermorken{at}uza.be
Purpose To evaluate the efficacy and safety of the epidermal growth factor receptordirected monoclonal antibody cetuximab administered as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN) who experience disease progression on platinum therapy.
Patients and Methods An open-label multicenter study in which patients with disease progression on two to six cycles of platinum therapy received single-agent cetuximab (initial dose 400 mg/m2 followed by subsequent weekly doses of 250 mg/m2) for 6 weeks (single-agent phase). Patients who experienced disease progression could receive salvage therapy with cetuximab plus platinum (combination-therapy phase). From June 2001 to December 2002, 103 patients were enrolled and treated with cetuximab, 53 of whom subsequently received combination therapy.
Results In the single-agent phase, response rate was 13%, disease control rate (complete response/partial response/stable disease) was 46%, and median time to progression (TTP) was 70 days. During the combination-therapy phase, the objective response rate was zero, disease control rate was 26%, and TTP was 50 days. Median overall survival was 178 days. Treatment was well tolerated. The most common cetuximab-related adverse events in the single-agent phase were skin reactions, particularly rash (49% of patients, mainly grade 1 or 2). There was one treatment-related death due to an infusion-related reaction.
Conclusion Single-agent cetuximab was active and generally well tolerated in the treatment of recurrent and/or metastatic SCCHN that progressed on platinum therapy. Response was comparable to that seen with cetuximab plus platinum combination regimens in the same setting.
Presented in part at the 40th Annual Meeting of the American Society of Clinical Oncology, June 5-8, 2004, New Orleans, LA.
Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

CiteULike Complore Connotea Del.icio.us Digg Facebook Reddit Technorati Twitter What's this?
Related Editorial
- Epidermal Growth Factor Receptor Inhibition in Head and Neck CancerMore Insights, but More Questions
Arlene A. Forastiere and Barbara A. Burtness
JCO 2007 25: 2152-2155
[Full Text]
This article has been cited by other articles:

|
 |

|
 |
 
T. M. Trippett, C. Herzog, J. A. Whitlock, J. Wolff, J. Kuttesch, R. Bagatell, S. P. Hunger, J. Boklan, A. A. Smith, R. J. Arceci, et al.
Phase I and Pharmacokinetic Study of Cetuximab and Irinotecan in Children With Refractory Solid Tumors: A Study of the Pediatric Oncology Experimental Therapeutic Investigators' Consortium
J. Clin. Oncol.,
October 20, 2009;
27(30):
5102 - 5108.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Lorenzen, T. Schuster, R. Porschen, S.-E. Al-Batran, R. Hofheinz, P. Thuss-Patience, M. Moehler, P. Grabowski, D. Arnold, T. Greten, et al.
Cetuximab plus cisplatin-5-fluorouracil versus cisplatin-5-fluorouracil alone in first-line metastatic squamous cell carcinoma of the esophagus: a randomized phase II study of the Arbeitsgemeinschaft Internistische Onkologie
Ann. Onc.,
October 1, 2009;
20(10):
1667 - 1673.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. I. Haddad, R. B. Tishler, C. Norris, L. Goguen, T. A. Balboni, R. Costello, L. Wirth, J. Lorch, B. Andreozzi, D. Annino, et al.
Phase I Study of C-TPF in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck
J. Clin. Oncol.,
September 20, 2009;
27(27):
4448 - 4453.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. M. Nutting, C. M. L. van Herpen, A. B. Miah, S. A. Bhide, J.-P. Machiels, J. Buter, C. Kelly, D. de Raucourt, and K. J. Harrington
Phase II study of 3-AP Triapine in patients with recurrent or metastatic head and neck squamous cell carcinoma
Ann. Onc.,
July 1, 2009;
20(7):
1275 - 1279.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Schoder, M. Fury, N. Lee, and D. Kraus
PET Monitoring of Therapy Response in Head and Neck Squamous Cell Carcinoma
J. Nucl. Med.,
May 1, 2009;
50(Suppl_1):
74S - 88S.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Y. Seiwert, R. Jagadeeswaran, L. Faoro, V. Janamanchi, V. Nallasura, M. El Dinali, S. Yala, R. Kanteti, E. E.W. Cohen, M. W. Lingen, et al.
The MET Receptor Tyrosine Kinase Is a Potential Novel Therapeutic Target for Head and Neck Squamous Cell Carcinoma
Cancer Res.,
April 1, 2009;
69(7):
3021 - 3031.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Y. Lai, P. Koppikar, S. M. Thomas, E. E. Childs, A. M. Egloff, R. R. Seethala, B. F. Branstetter, W. E. Gooding, A. Muthukrishnan, J. M. Mountz, et al.
Intratumoral Epidermal Growth Factor Receptor Antisense DNA Therapy in Head and Neck Cancer: First Human Application and Potential Antitumor Mechanisms
J. Clin. Oncol.,
March 10, 2009;
27(8):
1235 - 1242.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. B. Vermorken, R. Mesia, F. Rivera, E. Remenar, A. Kawecki, S. Rottey, J. Erfan, D. Zabolotnyy, H.-R. Kienzer, D. Cupissol, et al.
Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer
N. Engl. J. Med.,
September 11, 2008;
359(11):
1116 - 1127.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. I. Haddad and D. M. Shin
Recent Advances in Head and Neck Cancer
N. Engl. J. Med.,
September 11, 2008;
359(11):
1143 - 1154.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. R. Hirsch, R. S. Herbst, C. Olsen, K. Chansky, J. Crowley, K. Kelly, W. A. Franklin, P. A. Bunn Jr, M. Varella-Garcia, and D. R. Gandara
Increased EGFR Gene Copy Number Detected by Fluorescent In Situ Hybridization Predicts Outcome in Non-Small-Cell Lung Cancer Patients Treated With Cetuximab and Chemotherapy
J. Clin. Oncol.,
July 10, 2008;
26(20):
3351 - 3357.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. Ciardiello and G. Tortora
EGFR Antagonists in Cancer Treatment
N. Engl. J. Med.,
March 13, 2008;
358(11):
1160 - 1174.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. L. Dirks, A. Nolting, A. Kovar, and B. Meibohm
Population Pharmacokinetics of Cetuximab in Patients With Squamous Cell Carcinoma of the Head and Neck
J. Clin. Pharmacol.,
March 1, 2008;
48(3):
267 - 278.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. A. Forastiere and B. A. Burtness
Epidermal Growth Factor Receptor Inhibition in Head and Neck Cancer--More Insights, but More Questions
J. Clin. Oncol.,
June 1, 2007;
25(16):
2152 - 2155.
[Full Text]
[PDF]
|
 |
|
|